303 related articles for article (PubMed ID: 33762182)
1. Primary central nervous system lymphoma - ocular variant: an interdisciplinary review on management.
Raval V; Binkley E; Aronow ME; Valenzuela J; Peereboom DM; Singh AD
Surv Ophthalmol; 2021; 66(6):1009-1020. PubMed ID: 33762182
[TBL] [Abstract][Full Text] [Related]
2. Eye involvement in primary central nervous system lymphoma.
Farrall AL; Smith JR
Surv Ophthalmol; 2020; 65(5):548-561. PubMed ID: 32057762
[TBL] [Abstract][Full Text] [Related]
3. Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.
Chen T; Liu Y; Wang Y; Chang Q; Wu J; Wang Z; Geng D; Yu JT; Li Y; Li XQ; Chen H; Zhuang D; Li J; Wang B; Jiang T; Lyu L; Song Y; Qiu X; Li W; Lin S; Zhang X; Lu D; Lei J; Chen Y; Mao Y
J Hematol Oncol; 2022 Sep; 15(1):136. PubMed ID: 36176002
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and treatment of primary CNS lymphoma.
Korfel A; Schlegel U
Nat Rev Neurol; 2013 Jun; 9(6):317-27. PubMed ID: 23670107
[TBL] [Abstract][Full Text] [Related]
5. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.
Grimm SA; McCannel CA; Omuro AM; Ferreri AJ; Blay JY; Neuwelt EA; Siegal T; Batchelor T; Jahnke K; Shenkier TN; Hall AJ; Graus F; Herrlinger U; Schiff D; Raizer J; Rubenstein J; Laperriere N; Thiel E; Doolittle N; Iwamoto FM; Abrey LE
Neurology; 2008 Oct; 71(17):1355-60. PubMed ID: 18936428
[TBL] [Abstract][Full Text] [Related]
6. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract][Full Text] [Related]
7. The role of additional radiotherapy for primary central nervous system lymphoma.
Zacher J; Kasenda B; Engert A; Skoetz N
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009211. PubMed ID: 24931518
[TBL] [Abstract][Full Text] [Related]
8. Primary central nervous system lymphoma.
Schaff LR; Grommes C
Blood; 2022 Sep; 140(9):971-979. PubMed ID: 34699590
[TBL] [Abstract][Full Text] [Related]
9. Treatment options for central nervous system lymphomas in immunocompetent patients.
Jahnke K; Thiel E
Expert Rev Neurother; 2009 Oct; 9(10):1497-509. PubMed ID: 19831839
[TBL] [Abstract][Full Text] [Related]
10. Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma.
Zhuang L; Lai J; Chen K; Ding T; Yuan Y; Ma Y; Kang H; Lin Z; Fan N; Ma J; Zeng Q; Xu X; Wang Q; Chen B
Oncol Rep; 2019 Jan; 41(1):397-404. PubMed ID: 30320386
[TBL] [Abstract][Full Text] [Related]
11. Review of rituximab in primary CNS lymphoma.
Singh PK; Pan E
J Neurol Sci; 2020 Mar; 410():116649. PubMed ID: 31901591
[TBL] [Abstract][Full Text] [Related]
12. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma.
Grommes C; Rubenstein JL; DeAngelis LM; Ferreri AJM; Batchelor TT
Neuro Oncol; 2019 Feb; 21(3):296-305. PubMed ID: 30418592
[TBL] [Abstract][Full Text] [Related]
14. Advances in Primary Central Nervous System Lymphoma.
Patrick LB; Mohile NA
Curr Oncol Rep; 2015 Dec; 17(12):60. PubMed ID: 26475775
[TBL] [Abstract][Full Text] [Related]
15. A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma.
Steffanoni S; Calimeri T; Anzalone N; Mastaglio S; Bernardi M; Ferreri AJ
Expert Rev Hematol; 2022 Jan; 15(1):33-43. PubMed ID: 34904506
[TBL] [Abstract][Full Text] [Related]
16. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis and management of primary CNS lymphoma.
Roth P; Korfel A; Martus P; Weller M
Expert Rev Anticancer Ther; 2012 May; 12(5):623-33. PubMed ID: 22594897
[TBL] [Abstract][Full Text] [Related]
18. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
[TBL] [Abstract][Full Text] [Related]
19. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL).
Hoang-Xuan K; Deckert M; Ferreri AJM; Furtner J; Gallego Perez-Larraya J; Henriksson R; Hottinger AF; Kasenda B; Lefranc F; Lossos A; McBain C; Preusser M; Roth P; Rudà R; Schlegel U; Soffietti R; Soussain C; Taphoorn MJB; Touitou V; Weller M; Bromberg JEC
Neuro Oncol; 2023 Jan; 25(1):37-53. PubMed ID: 35953526
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in primary CNS lymphoma.
Hoang-Xuan K; Camilleri-Broët S; Soussain C
Curr Opin Oncol; 2004 Nov; 16(6):601-6. PubMed ID: 15627024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
